CD274 and neoplasm: However, there are some limitations regarding immune checkpoint inhibitors in this study: Over half of the LUAD patients are not markedly sensitive to PD-1/PD-L1 antitumor immunotherapy, indicating the existence of additional immunotherapeutic biomarkers in the LUAD tumor microenvironment (9).